Advertisement

Tumor Biology

, Volume 34, Issue 6, pp 3887–3892 | Cite as

Quantitative assessment of the relationship between p21 Ser31Arg polymorphism and cervical cancer

  • Yingchun Ma
  • Yanwei Zhang
  • Li Lin
  • Xiumin Guo
  • Yu Wu
  • Wenjuan Wen
  • Fengli Li
  • Peishu Liu
Research Article

Abstract

Though many studies were published to assess the relationship between p21 Ser31Arg polymorphism and cervical cancer, there was no definite conclusion on this association. To provide a quantitative assessment of the relationship between p21 Ser31Arg polymorphism and cervical cancer, we performed a meta-analysis of 10 eligible studies (1,539 cases and 2,161 controls). All those 10 studies were from Asians. The odds ratios (OR) with 95 % confidence intervals (95 %CIs) were used to assess the strength of the association, and the pooled ORs were calculated for the codominant model (ArgArg vs. SerSer), the dominant model (ArgArg/SerArg vs. SerSer), and the recessive model (ArgArg vs. SerSer/SerArg). Meta-analysis of those 10 studies showed that there was no association between p21 Ser31Arg polymorphism and cervical cancer risk in Asians under all three models (ArgArg vs. SerSer: OR = 1.04, 95 %CI 0.66–1.65, P = 0.86, I 2 = 78 %; ArgArg/SerArg vs. SerSer: OR = 0.93, 95 %CI 0.66–1.30, P = 0.66, I 2 = 81 %; ArgArg vs. SerSer/SerArg: OR = 1.20, 95 %CI 0.84–1.73, P = 0.32, I 2 = 72 %). Sensitivity analysis performed by omitting each study in turn showed that the pooled results were stable. In summary, there is no association between p21 Ser31Arg polymorphism and cervical cancer risk in Asians. Further studies are needed to assess the possible association between p21 Ser31Arg polymorphism and cervical cancer risk in Caucasians.

Keywords

p21 Polymorphism Cervical cancer Meta-analysis 

References

  1. 1.
    Shepherd JH. Cervical cancer. Best Pract Res Clin Obstet Gynaecol. 2012;26:293–309.PubMedCrossRefGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.PubMedCrossRefGoogle Scholar
  3. 3.
    Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907.PubMedCrossRefGoogle Scholar
  4. 4.
    Albrow R, Kitchener H, Gupta N, Desai M. Cervical screening in England: the past, present, and future. Cancer Cytopathol. 2012;120:87–96.PubMedCrossRefGoogle Scholar
  5. 5.
    de Freitas AC, Gurgel AP, Chagas BS, Coimbra EC, do Amaral CM. Susceptibility to cervical cancer: an overview. Gynecol Oncol. 2012;126:304–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Psyrri A, DiMaio D. Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol. 2008;5:24–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Rowland BD, Peeper DS. Klf4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer. 2006;6:11–23.PubMedCrossRefGoogle Scholar
  8. 8.
    Abbas T, Dutta A. P21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400–14.PubMedCrossRefGoogle Scholar
  9. 9.
    Liu G, Lozano G. P21 stability: linking chaperones to a cell cycle checkpoint. Cancer Cell. 2005;7:113–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Kumar R, Gururaj AE, Barnes CJ. P21-activated kinases in cancer. Nat Rev Cancer. 2006;6:459–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Lei D, Sturgis EM, Liu Z, Zafereo ME, Wei Q, Li G. Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Carcinogenesis. 2010;31:222–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Van den Broeke C, Radu M, Chernoff J, Favoreel HW. An emerging role for p21-activated kinases (paks) in viral infections. Trends Cell Biol. 2010;20:160–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Harima Y, Sawada S, Nagata K, Sougawa M, Ostapenko V, Ohnishi T. Polymorphism of the waf1 gene is related to susceptibility to cervical cancer in Japanese women. Int J Mol Med. 2001;7:261–4.PubMedGoogle Scholar
  14. 14.
    Roh J, Kim M, Kim J, Park N, Song Y, Kang S, et al. Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett. 2001;165:59–62.PubMedCrossRefGoogle Scholar
  15. 15.
    Lee JE, Lee SJ, Namkoong SE, Um SJ, Sull JW, Jee SH, et al. Gene-gene and gene-environmental interactions of p53, p21, and irf-1 polymorphisms in Korean women with cervix cancer. Int J Gynecol Cancer. 2004;14:118–25.PubMedCrossRefGoogle Scholar
  16. 16.
    Lee SA, Kim JW, Roh JW, Choi JY, Lee KM, Yoo KY, et al. Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women. Gynecol Oncol. 2004;93:14–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Bhattacharya P, Sengupta S. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women. Gynecol Oncol. 2005;99:176–82.PubMedCrossRefGoogle Scholar
  18. 18.
    Tian Q, Lu W, Chen H, Ye F, Xie X. The nonsynonymous single-nucleotide polymorphisms in codon 31 of p21 gene and the susceptibility to cervical cancer in Chinese women. Int J Gynecol Cancer. 2009;19:1011–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Jiang P, Liu J, Li W, Zeng X, Tang J. Role of p53 and p21 polymorphisms in the risk of cervical cancer among Chinese women. Acta Biochim Biophys Sin (Shanghai). 2010;42:671–6.CrossRefGoogle Scholar
  20. 20.
    Roh JW, Kim BK, Lee CH, Kim J, Chung HH, Kim JW, et al. P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. Oncol Res. 2010;18:453–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Wang N, Wang S, Zhang Q, Lu Y, Wei H, Li W, et al. Association of p21 SNPs and risk of cervical cancer among Chinese women. BMC Cancer. 2012;12:589.PubMedCrossRefGoogle Scholar
  22. 22.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  23. 23.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  24. 24.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  25. 25.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Yang A, Zheng X, Tao L, Jiang J, Fu J, Jia W, et al. P53arg72pro, p21ser31arg polymorphism and cervical cancer susceptibility in Xinjiang Uygur population. J Shihezi Univ. 2008;26:6–11.Google Scholar
  27. 27.
    Vasilevska M, Ross SA, Gesink D, Fisman DN. Relative risk of cervical cancer in indigenous women in Australia, Canada, New Zealand, and the United States: a systematic review and meta-analysis. J Public Health Policy. 2012;33:148–64.PubMedCrossRefGoogle Scholar
  28. 28.
    Li Y, Liu F, Tan SQ, Wang Y, Li SW. X-ray repair cross-complementing group 1 (nxrcc1) genetic polymorphisms and cervical cancer risk: a huge systematic review and meta-analysis. PLoS One. 2012;7:e44441.PubMedCrossRefGoogle Scholar
  29. 29.
    Liu F, Wei YG, Luo LM, Wang WT, Yan LN, Wen TF, et al. Genetic variants of p21 and p27 and hepatocellular cancer risk in a Chinese Han population: a case–control study. Int J Cancer. 2013;132:2056–64.PubMedCrossRefGoogle Scholar
  30. 30.
    Lin G, Fang F, Yu XJ, Yu L. Meta-analysis of the relationship between p21 Ser31Arg polymorphism and lung cancer susceptibility. Genet Mol Res. 2011;10:2449–56.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Yingchun Ma
    • 1
    • 2
  • Yanwei Zhang
    • 3
  • Li Lin
    • 2
  • Xiumin Guo
    • 2
  • Yu Wu
    • 2
  • Wenjuan Wen
    • 4
  • Fengli Li
    • 2
  • Peishu Liu
    • 1
  1. 1.Department of Gynecology and Obstetrics, Qilu HospitalShandong UniversityJinanPeople’s Republic of China
  2. 2.Department of Obstetrics and GynecologyLiaocheng People’s Hospital and Liaocheng Clinical School of Taishan Medical UniversityLiaochengPeople’s Republic of China
  3. 3.Department of AnesthesiologyLiaocheng People’s Hospital and Liaocheng Clinical School of Taishan Medical UniversityLiaochengPeople’s Republic of China
  4. 4.Department of PathologyLiaocheng People’s Hospital and Liaocheng Clinical School of Taishan Medical UniversityLiaochengPeople’s Republic of China

Personalised recommendations